REM sleep behavior disorder (RBD)¹¹ REM sleep behavior disorder (RBD)
During RBD, the normal motor paralysis of REM sleep fails, causing people to act out their dreams — punching, kicking, yelling. It is the strongest single predictor of Parkinson's disease and Lewy body dementia: over 80% of those diagnosed with idiopathic RBD eventually convert to a synucleinopathy within 14 years. is no ordinary sleep disturbance. It sits at the far upstream end of the Parkinson's disease continuum — years before motor symptoms emerge and dopamine neurons begin to die. This variant, rs117896735, sits in an intron of the INPP5F gene and emerged from the first major RBD GWAS as one of only five loci reaching genome-wide significance out of the entire human genome.

The locus spans two genes: INPP5F, which encodes an enzyme called Sac2²² Sac2
INPP5F is also known as Sac2 — a member of the SAC phosphatase family that dephosphorylates phosphatidylinositol 4-phosphate on endosomal membranes, and BAG3, a co-chaperone that sits at the intersection of two major protein-disposal systems.

The Mechanism

INPP5F/Sac2 controls the phosphoinositide composition of endosomal membranes. It functions as a PI4P phosphatase³³ PI4P phosphatase
Phosphatidylinositol 4-phosphate is a lipid signal that recruits trafficking proteins to endosomes; its timely removal is required for endosomal cargo sorting and recycling, dephosphorylating PI(4)P in concert with OCRL to regulate endocytic recycling — the same pathway by which alpha-synuclein aggregates are routed toward lysosomal degradation. Disruption of this pathway impairs autophagosome loading and delays clearance of misfolded proteins before they can seed Lewy body formation.

Immediately neighboring INPP5F, BAG3⁴⁴ BAG3
BCL2-associated athanogene 3 — a co-chaperone that bridges Hsp70 and autophagy receptor p62/SQSTM1 to direct misfolded client proteins into autophagosomes rather than the proteasome orchestrates the switch from proteasomal degradation to selective macroautophagy when the proteasome is overwhelmed by misfolded proteins — precisely the scenario in aging neurons accumulating alpha-synuclein. BAG3 forms a trimeric complex with Hsp70 and p62/SQSTM1, colocalizing with autophagy markers in brain tissue. When BAG3 is overexpressed, alpha-synuclein clearance via macroautophagy increases in an Atg5-dependent manner; when BAG3 is reduced, toxic alpha-synuclein accumulates.

rs117896735 is an intronic variant, so it does not alter either protein's coding sequence. It is most likely a regulatory variant⁵⁵ regulatory variant
eQTL studies at this locus did not reach significance in the Krohn 2022 dataset, but the proximity to regulatory elements controlling INPP5F and BAG3 expression in dopaminergic neurons is consistent with the locus's functional effect on protein quality control influencing transcriptional output of INPP5F, BAG3, or both — subtly reducing the brain's capacity to clear misfolded proteins through the endolysosomal-autophagic axis.

The Evidence

The landmark genome-wide association study by Krohn et al. 2022⁶⁶ Krohn et al. 2022
Meta-analysis of iRBD + PD-with-probable-RBD cohorts spanning multiple European and North American sites combined 2,843 RBD cases with 139,636 controls, identifying rs117896735 with an odds ratio of 1.80 (95% CI 1.48–2.19, p=4.70×10⁻⁹). The A allele effect was consistent across the isolated RBD cohort (OR 1.88) and the PD-with-probable-RBD cohort (OR 1.57), supporting genuine association rather than a population-specific artefact. The A allele frequency in the GWAS was approximately 2% — enriched above the gnomAD European frequency of ~1.4% — consistent with a variant under mild purifying selection for its risk effect.

This OR of 1.80 is large by GWAS standards⁷⁷ large by GWAS standards
Common GWAS hits for common diseases typically show OR 1.05–1.20; OR ≥ 1.5 is uncommon for a common variant and suggests meaningful biological impact on the pathway. The four other genome-wide significant RBD loci map to SNCA (alpha-synuclein itself), GBA (lysosomal glucocerebrosidase), TMEM175 (lysosomal K⁺ channel), and SCARB2 (lysosomal membrane protein) — all genes with direct roles in lysosomal protein degradation. The INPP5F/BAG3 locus fits this pattern: upstream phosphoinositide regulation feeding into the same autophagic clearance axis.

On the BAG3 side, Cao et al. 2017⁸⁸ Cao et al. 2017
Cell-based and transgenic mouse study demonstrating BAG3's role in Atg5-dependent selective macroautophagy of alpha-synuclein directly demonstrated that BAG3 modulates alpha-synuclein quality control in dopaminergic neurons. Ying et al. 2022⁹⁹ Ying et al. 2022
Mouse striatal BAG3 overexpression reduced dopaminergic neuron loss and microglial activation following inflammatory challenge extended this to show BAG3 also suppresses NLRP3 inflammasome activation, adding a neuroinflammatory dimension to the locus's relevance.

Practical Implications

The A allele does not cause RBD; it shifts the probability. At OR 1.80 with a baseline population RBD prevalence of roughly 0.5–1%, even A allele carriers face an absolute lifetime risk well below 5% in isolation. However, RBD is itself a prodromal state for synucleinopathies with ~80% conversion rates over 14 years. The practical value of knowing this genotype lies in motivating early surveillance and lifestyle choices that support the protein-clearance pathway that this locus modulates.

The autophagic axis is specifically addressable: sleep architecture itself¹⁰¹⁰ sleep architecture itself
Deep slow-wave sleep drives glymphatic clearance of alpha-synuclein from the brain via the perivascular space; RBD reduces slow-wave sleep independently of its motor symptoms drives the glymphatic clearance of brain alpha-synuclein. Prioritizing sleep quality and continuity is therefore directly relevant to the locus's biology.

Interactions

The INPP5F/BAG3 locus connects to other RBD and Parkinson's risk variants through the shared autophagic-lysosomal clearance pathway. GBA variants (rs76763715, rs34637584) impair lysosomal glucocerebrosidase activity, creating downstream substrate backlog in the same pathway. SNCA variants (rs356182) directly affect alpha-synuclein expression and aggregation propensity. TMEM175 variants (rs34311866) impair lysosomal acidification required for autophagic cargo degradation. Carriers of multiple risk alleles across these loci may carry compounded reductions in protein-clearance capacity — a polygenic load on the same biological axis.

NPAS2 (Neuronal PAS Domain Protein 2) is the brain-specific paralog of the master circadian clock gene CLOCK. In the forebrain and limbic system, NPAS2 forms heterodimers with BMAL1 to drive the transcription of downstream clock-controlled genes — those that regulate sleep timing, hormone secretion, cell-cycle checkpoints, and DNA repair. NPAS2 is expressed predominantly in the cortex, hippocampus, and striatum¹¹ NPAS2 is expressed predominantly in the cortex, hippocampus, and striatum
Unlike CLOCK, which is expressed ubiquitously, NPAS2 provides brain-specific circadian rhythm generation. The rs1369481 variant sits within an intron of NPAS2 and has been studied primarily in the context of cancer risk — but the evidence for this specific variant is currently limited to a single unreplicated study.

The Variant

Rs1369481 is an intronic single nucleotide variant in which the common allele is C (~79% globally) and the minor allele is T (~21%). The T allele is the GRCh38 reference base at this position, but it is the minor allele in every major population database. The variant does not change the NPAS2 protein sequence — it sits within an intron — and its functional consequence, if any, is unknown. CADD scores (C allele: 5.1, T allele: 4.8) place this well below the threshold typically associated with functional significance. No regulatory feature disruption has been experimentally confirmed.

The Evidence

The primary study naming rs1369481 is Zhu et al. 2009 (Cancer Research)²² Zhu et al. 2009 (Cancer Research)
Testing the Circadian Gene Hypothesis in Prostate Cancer: A Population-Based Case-Control Study, a candidate-gene study of 1,308 prostate cancer cases and 1,266 controls among Caucasian men. The investigators genotyped 41 SNPs across 10 circadian genes and found rs1369481 to be among 11 variants significantly associated with prostate cancer susceptibility — either overall or for aggressive disease. NPAS2 was the only gene with three independent associated variants.

Critical limitation: This study has not been independently replicated for rs1369481 specifically. Two subsequent EPICAP studies by Wendeu-Foyet et al. 2019 (Int J Cancer)³³ Wendeu-Foyet et al. 2019 (Int J Cancer)
Circadian genes and risk of prostate cancer: Findings from the EPICAP study and 2020⁴⁴ 2020
Circadian genes polymorphisms, night work and prostate cancer risk replicated NPAS2 gene-level associations with prostate cancer (including among night workers), but found that no individual SNP reached significance — consistent with rs1369481 being a weak signal within a gene that collectively shows circadian-cancer links. The GWAS Catalog contains no genome-wide significant associations for rs1369481. ClinVar has no entry for this variant.

Separate from prostate cancer, the broader NPAS2 literature documents cancer-relevant biology: Zhu et al. 2007 (Int J Cancer)⁵⁵ Zhu et al. 2007 (Int J Cancer)
Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma found that the NPAS2 Ala394Thr variant (rs2305160, a different coding SNP) reduced NHL risk by 34% (OR=0.66, 95% CI 0.51-0.85). This provides biological plausibility — NPAS2 participates in circadian regulation of DNA repair and cell-cycle checkpoints — but does not validate rs1369481 specifically.

For mood and sleep, Soria et al. 2010 (Neuropsychopharmacology)⁶⁶ Soria et al. 2010 (Neuropsychopharmacology)
CRY1 and NPAS2 associated with unipolar major depression identified NPAS2 rs11123857 (not rs1369481) as associated with major depressive disorder in 534 mood disorder patients. Shift-work studies have documented NPAS2 polymorphism effects on sleep phase and daytime sleepiness, again using different SNPs in the gene.

Bottom line on evidence: The association between rs1369481 and prostate cancer is based on one study with no replication, no genome-wide significance, and no known functional mechanism. The honest evidence grade is emerging. Users with the T allele should be aware of this signal but should not treat it as established risk.

Practical Implications

For men carrying the T allele (TC or TT genotype), the available evidence supports discussing prostate cancer screening timing with their physician — not because this variant alone confers high risk, but because it is one of several circadian gene signals associated with prostate cancer in studies of men with European ancestry. Standard PSA testing guidelines apply; this variant does not yet justify altered surveillance schedules on its own.

For circadian health generally: NPAS2 function depends on consistent light-dark cycle entrainment. Regular wake times, morning light exposure, and avoiding artificial light after dark support NPAS2-BMAL1 heterodimer activity regardless of genotype.

For women and for sleep phenotypes: No replicated evidence exists linking rs1369481 to sleep timing, chronotype, mood disorders, or any female-specific outcome.

Interactions

NPAS2 works in concert with CLOCK (its paralog) and the repressor arm of the circadian clock: CRY1, CRY2, PER1, PER2, PER3. Loss of NPAS2 function is partially compensated by CLOCK in most tissues, but not in the forebrain. The CRY1 splice variant rs184039278 (CRY1Δ11), associated with Delayed Sleep Phase Disorder, affects the same transcriptional complex that NPAS2 drives. Whether rs1369481 and CRY1 variants interact additively has not been studied.

The NPAS2 Ala394Thr coding variant (rs2305160) is more extensively studied and is a stronger candidate for cancer risk modification than rs1369481. Individuals who want to assess NPAS2 cancer biology should prioritize rs2305160 data where available.

The region between the IL23R¹¹ IL23R
interleukin-23 receptor gene, encoding the cytokine-binding subunit of the receptor complex that captures interleukin-23 and initiates downstream Th17 cell activation and IL12RB2 genes on chromosome 1p31.3 has emerged as one of the most replicated non-HLA autoimmune risk loci across three distinct diseases — Behçet's disease, ankylosing spondylitis, and Crohn's disease. rs1495965 is an intergenic variant within this region that tags a functional haplotype independently associated with each of these IL-23-driven inflammatory conditions. It is not the same signal as the well-known IL23R R381Q protective variant rs11209026²² IL23R R381Q protective variant rs11209026
a missense change that directly reduces IL-23 receptor function and strongly protects against IBD, psoriasis, and AS; rs1495965 is a separate, independent association captured by a different LD block in the same region — it captures an independent source of IL-23 pathway variation at this locus.

The Mechanism

rs1495965 sits in the intergenic space between IL23R and IL12RB2, roughly 80 kb downstream of the IL23R coding sequence. As an intergenic/regulatory variant³³ intergenic/regulatory variant
a change in non-coding DNA that may alter transcription factor binding sites, enhancer elements, or regulatory regions controlling adjacent gene expression, it does not alter either receptor protein's amino acid sequence. The fine-mapping study⁴⁴ fine-mapping study
Cheon et al. 2017 Korean cohort — 453 BD cases, 2,283 controls — found rs1495965 in r²=0.99 linkage disequilibrium with two flanking variants (rs1495966, rs4655535), all localized to the intergenic region rather than the two flanking gene bodies establishes that the disease signal emanates from a regulatory element in the gap between the two receptor genes rather than from their coding sequences.

The likely mechanism involves altered expression or isoform balance of IL23R, IL12RB2, or both. Both encode receptor subunits for cytokines in the interleukin-12 family — IL23R pairs with IL12RB1 to form the IL-23 receptor, while IL12RB2 pairs with IL12RB1 for the IL-12 receptor. Regulatory variants in this region can shift the balance of Th17 versus Th1 immune responses by modulating which cytokine signal dominates T cell polarization. The net consequence of the risk haplotype is a subtly amplified IL-23/Th17 axis — the same axis that drives inflammation in the gut mucosa, spinal entheses, and uveal tissue of the eye.

The Evidence

The original association was identified in a genome-wide association study of Behçet's disease⁵⁵ genome-wide association study of Behçet's disease
Mizuki N et al., Nature Genetics, 2010 — initial Japanese cohort of 612 cases and 740 controls, confirmed in Turkish and Korean replication cohorts, which found rs1495965 at p=2×10⁻¹¹ with OR 1.35 (95% CI 1.24–1.47). Behçet's disease is a systemic vasculitis with inflammatory ulcers, joint involvement, and uveitis that is particularly prevalent in populations along the ancient Silk Road from the Middle East to East Asia. A 2018 clinical study of Behçet's uveitis⁶⁶ 2018 clinical study of Behçet's uveitis
Habot-Wilner et al. — Turkish and Middle Eastern Israeli patients found the risk allele in 77–79% of Behçet's uveitis patients versus only 27.8% of controls, underscoring how dominant this locus is in those ancestral backgrounds.

Korean fine-mapping⁷⁷ fine-mapping
Cheon et al. 2017 confirmed the signal with OR 1.5 (95% CI 1.3–1.7, p=2.5×10⁻⁷) and established that the three correlated variants (rs1495965, rs1495966, rs4655535) are effectively interchangeable tags for the same causal regulatory element.

For ankylosing spondylitis, a meta-analysis of 25 studies comprising 8,431 AS cases and 8,972 controls⁸⁸ meta-analysis of 25 studies comprising 8,431 AS cases and 8,972 controls
Zhong et al., Expert Review of Clinical Immunology, 2018 found the C allele at rs1495965 significantly enriched in AS cases across populations (p<0.001), identifying it as one of three IL23R-region variants with independently replicated AS susceptibility signals.

For Crohn's disease, a Korean pediatric cohort study⁹⁹ Korean pediatric cohort study
Kim et al. 2019 — 141 pediatric CD cases, 150 controls found risk allele OR 1.484 (p=0.018), with homozygous carriers at OR 2.256. Homozygous risk carriers were also more likely to develop penetrating or stenotic disease behavior — the more complicated CD phenotypes associated with worse long-term outcomes.

The evidence across three diseases is rated strong based on genome-wide significance in the original GWAS, independent replication across multiple ancestries, and a formal meta-analysis for AS. Effect sizes are modest (OR 1.35–1.5 per allele), consistent with the polygenic architecture of these conditions.

Practical Implications

The three conditions linked to rs1495965 — Behçet's disease, ankylosing spondylitis, and Crohn's disease — share the IL-23/Th17 inflammatory axis, and their genetic overlap at this locus reflects their shared pathobiology. Carrying one or two copies of the C risk allele elevates susceptibility to all three, and the diseases can co-occur in the same individual.

For Behçet's disease, the hallmark features are recurrent oral ulcers, genital ulcers, uveitis, and skin lesions. The condition is most prevalent in Middle Eastern, Turkish, and East Asian backgrounds. Unexplained recurrent oral ulcers — especially if accompanied by genital ulceration or eye inflammation — warrant rheumatology evaluation.

For ankylosing spondylitis, the key early symptom is inflammatory back pain: onset before age 45, worse at rest and at night, improving with movement and NSAIDs, with morning stiffness lasting more than 30 minutes. Early diagnosis with sacroiliac joint MRI enables treatment before structural fusion occurs.

For Crohn's disease, symptoms include persistent diarrhea, abdominal pain, blood in stool, and unintended weight loss. The pediatric data suggesting more penetrating disease behavior in homozygous risk carriers makes earlier endoscopic evaluation and proactive treatment escalation appropriate if CD is diagnosed.

All three conditions are treated with immunosuppressive therapies targeting the IL-23/Th17 axis, including IL-23 inhibitors¹⁰¹⁰ IL-23 inhibitors
risankizumab, guselkumab, tildrakizumab — approved for Crohn's disease, AS, and psoriasis/PsA; ustekinumab targets the shared IL-12/23 p40 subunit and IL-17 inhibitors.

Interactions

rs1495965 tags an independent signal from the other IL23R variants in the database. rs1004819 and rs2201841 each reside in different LD blocks within the IL23R locus — rs1004819 within an IL23R intron, rs2201841 in a separate intronic region, and rs1495965 in the downstream intergenic region. These three variants capture distinct regulatory effects on the same IL-23 pathway and may have additive susceptibility when risk alleles are co-inherited, though formal interaction analysis has not been published.

The protective missense variant rs11209026 (R381Q) is in the IL23R coding sequence and reduces receptor surface expression — it operates through a fundamentally different mechanism (protein loss-of-function) compared to the regulatory effects of rs1495965. Individuals carrying C risk alleles at rs1495965 who also carry the R381Q protective allele may have partially attenuated risk, as the coding change reduces receptor activity regardless of the regulatory signal from the intergenic region.

Aggrecan is the workhorse proteoglycan¹¹ workhorse proteoglycan
ACAN encodes aggrecan, which comprises roughly 50% of the dry weight of the nucleus pulposus in intervertebral discs and is the primary proteoglycan providing compressive resistance in articular cartilage of your joints and spine. It's a massive molecule — over 2,500 amino acids with heavily glycosylated side chains that trap water, creating the gel-like matrix that cushions cartilage under load. Every time you sprint, jump, or pivot, aggrecan is what keeps your knee cartilage from collapsing like a deflated tire.

The rs1516797 variant sits in an intronic region of the ACAN gene on chromosome 15. While it doesn't directly change the aggrecan protein sequence, it appears to affect gene expression or mRNA splicing, ultimately influencing how much functional aggrecan your cartilage produces. This matters enormously for athletes in high-impact sports — especially football, where repetitive loading stresses the ACL, knee cartilage, and spinal discs.

The Mechanism

As an intronic regulatory variant, rs1516797 likely influences ACAN transcription levels or alternative splicing efficiency. Lower aggrecan expression²² Lower aggrecan expression
Individuals with fewer CS (chondroitin sulfate) chains on aggrecan may have reduced osmotic pressure in cartilage, increasing susceptibility to degeneration means less water retention in the cartilage matrix, reducing its ability to distribute compressive forces. Over time, this leads to accelerated wear — both in weight-bearing joints and intervertebral discs.

The G allele appears to be the risk variant. In the context of ACL injury, G carriers show increased susceptibility³³ G carriers show increased susceptibility
Mannion et al. found the G allele was under-represented in controls (OR=0.72, 95% CI 0.55-0.96, p=0.024), suggesting T/T individuals have better cartilage resilience and lower ACL rupture risk, though the exact mechanism linking aggrecan to ligament integrity likely involves the cartilage-bone interface and overall joint stability.

The Evidence

Mannion et al. (2014)⁴⁴ Mannion et al. (2014)
Mannion S, et al. Genes encoding proteoglycans are associated with the risk of anterior cruciate ligament ruptures. Br J Sports Med. 2014 studied 227 ACL rupture patients and 234 controls in a South African cohort. The T/T genotype was over-represented in controls, suggesting a protective effect (OR for the G allele = 1.38 for increased risk, or conversely OR=0.72 for the protective T allele). This was one of the first studies to identify ACAN variants as ACL injury modifiers.

A 2022 systematic review⁵⁵ A 2022 systematic review
A comprehensive review of genetic predisposition to injury in football identified rs1516797 as one of only three SNPs with replicated findings across independent professional football cohorts, alongside ACTN3 rs1815739 and VEGFA rs2010963 across multiple football studies confirmed rs1516797 as one of only three genetic variants with replicated injury associations in independent cohorts — the others being ACTN3 (rs1815739) and VEGFA (rs2010963). This replication across populations strengthens the evidence, though methodological limitations (small samples, population stratification) mean genetic testing isn't yet clinically validated for injury prediction.

Beyond ACL injury, Videman et al. (2009)⁶⁶ Videman et al. (2009)
Finnish males (n=588, ages 35-70) showed rs1516797 association with disc height narrowing, a hallmark of intervertebral disc degeneration linked rs1516797 to disc height narrowing in 588 Finnish men aged 35-70. Disc height loss is an early marker of disc degeneration — the same aggrecan deficiency that affects knee cartilage also compromises spinal disc hydration and shock absorption.

The protective effect of higher aggrecan expression isn't limited to injury prevention. Aggrecan loss is an early OA marker⁷⁷ Aggrecan loss is an early OA marker
Loss of aggrecan from articular cartilage is an early event in osteoarthritis development, with continued loss leading to irreversible collagen network damage. Maintaining robust aggrecan levels throughout a long athletic career may reduce post-traumatic osteoarthritis risk after ACL injuries or other joint trauma.

Practical Actions

If you carry one or two copies of the G allele, you're starting with slightly less cartilage resilience than T/T individuals. This doesn't mean you're destined for injury — it means you need to be more deliberate about cartilage protection and neuromuscular injury prevention.

For active athletes (especially football, basketball, soccer, skiing): Neuromuscular training cuts ACL risk by 50%⁸⁸ Neuromuscular training cuts ACL risk by 50%
Systematic reviews show neuromuscular training reduces overall knee injury risk by 22% and ACL injury risk by 50% in team sport athletes, with programs like FIFA 11+ reducing ACL injuries fourfold. Programs like FIFA 11+ have been shown to reduce ACL injuries by up to 73% through targeted balance, eccentric strength, and plyometric training. If you have genetic cartilage vulnerability, injury prevention protocols aren't optional — they're essential infrastructure.

Nutritional support for cartilage includes the building blocks aggrecan needs: vitamin C for collagen cross-linking⁹⁹ vitamin C for collagen cross-linking
Vitamin C is crucial for collagen production and acts as an antioxidant protecting joint tissues from free radical damage, glucosamine and chondroitin for aggrecan synthesis¹⁰¹⁰ glucosamine and chondroitin for aggrecan synthesis
Glucosamine increases aggrecan and type II collagen in cartilage, with studies supporting 1500 mg glucosamine and 1200 mg chondroitin daily in divided doses, and omega-3s for anti-inflammatory effects. The evidence for glucosamine/chondroitin is moderate — it won't rebuild damaged cartilage, but it may slow degradation and support ongoing synthesis.

Long-term joint health: Avoid chronic high-impact loading without adequate recovery. G/G individuals especially should prioritize cross-training with low-impact modalities (swimming, cycling) to reduce cumulative cartilage stress. Maintaining healthy body weight reduces joint loading — every extra kilogram adds 3-4 kg of force across the knee during walking.

Interactions

ACAN rs1516797 is one vertex in a broader genetic injury risk network. The other two replicated injury SNPs in football cohorts are ACTN3 rs1815739¹¹¹¹ ACTN3 rs1815739
The ACTN3 XX genotype (loss of alpha-actinin-3 in fast-twitch fibers) is associated with increased non-contact muscle injury risk and may compound ACL vulnerability (alpha-actinin-3 deficiency increases muscle injury risk and may compound ACL vulnerability) and VEGFA rs2010963¹²¹² VEGFA rs2010963
The VEGFA rs2010963 CC genotype is associated with increased ligament and tendon injury risk, potentially through altered vascular supply to connective tissues (vascular endothelial growth factor affects blood supply to ligaments and tendons). An individual carrying risk alleles at all three loci may have multiplicatively higher injury susceptibility.

COL5A1 rs12722¹³¹³ COL5A1 rs12722
The COL5A1 rs12722 CC genotype is associated with increased soft tissue injury risk through altered type V collagen structure, which regulates collagen fibril assembly affects type V collagen, a key regulator of collagen fibril diameter in tendons and ligaments. Since aggrecan interacts with the collagen network in cartilage, variants affecting both proteoglycan and collagen structure may synergistically increase injury risk.

The aggrecan-collagen relationship is critical: aggrecan provides compressive resistance, while type II collagen provides tensile strength. Loss of aggrecan exposes collagen to degradation¹⁴¹⁴ Loss of aggrecan exposes collagen to degradation
Continued aggrecan loss leads to susceptibility of the collagen network to proteolysis and irreversible cartilage damage. This suggests that combining ACAN risk variants with collagen gene variants (COL5A1, COL1A1) may accelerate cartilage degeneration.

Gene-Gene Interaction Proposals for Compound Actions

ACAN rs1516797 G + ACTN3 rs1815739 XX: Combined fast-twitch fiber deficiency and cartilage vulnerability increase both muscle and joint injury risk. Recommend prioritizing neuromuscular training (FIFA 11+), eccentric strengthening, and cartilage support (glucosamine/chondroitin + vitamin C). Evidence level: moderate.

ACAN rs1516797 GG + COL5A1 rs12722 CC: Double proteoglycan-collagen vulnerability affects both matrix components. Recommend aggressive injury prevention protocols, low-impact cross-training, and comprehensive joint support (collagen peptides 20-25g daily with vitamin C, glucosamine 1500mg + chondroitin 1200mg). Evidence level: moderate.

ACAN rs1516797 G + VEGFA rs2010963 CC: Cartilage vulnerability combined with impaired vascular supply to connective tissues. Recommend omega-3 supplementation (1-2g EPA/DHA daily) for anti-inflammatory and vascular support, plus standard cartilage nutrients. Evidence level: preliminary.

Interleukin-6 (IL-6) is the central cytokine of inflammaging¹¹ inflammaging
the chronic, low-grade sterile inflammation that accumulates with age and underlies most age-related diseases — first described by Franceschi et al. in 2000. Serum IL-6 concentrations rise two- to four-fold between age 20 and 80 in healthy adults, and this rise is not incidental — it predicts cardiovascular events, cognitive decline, muscle loss, frailty, and all-cause mortality better than almost any other biomarker. rs1524107 is an intronic variant in the IL6 gene (chromosome 7p15.3) that acts as a tag for one of the most functionally important haplotypes in the gene's regulatory architecture.

The Mechanism

rs1524107 sits in intron 2 of IL6 at GRCh38 position 22,728,600, where the gene runs along the plus strand. The variant itself is intronic — it does not change an amino acid — but it is in high linkage disequilibrium²² linkage disequilibrium
a statistical measure of how often two alleles are inherited together; r²>0.8 means the alleles are nearly always co-inherited (r²≈0.92) with the promoter variant rs1800796 and with rs2066992 in intron 4. Together these three SNPs define a haplotype tagged rs1800796-C / rs1524107-T / rs2066992-T that is common in East Asia (>75% frequency) but rare in Europeans (~5%).

Lo et al. 2021 in mBio³³ Lo et al. 2021 in mBio
A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19 showed that the T-allele haplotype disrupts a conserved CTCF⁴⁴ CTCF
CCCTC-binding factor, a master architectural protein that organises chromatin loops and regulates gene expression binding site at an intronic enhancer of the IL6 antisense lncRNA IL-6-AS1. Loss of this CTCF anchor reduces the chromatin looping that normally amplifies IL6 transcription during inflammatory stimuli. Cells from haplotype carriers respond poorly to LPS and viral challenge — producing less IL-6 — which protects against cytokine-storm hyperinflammation but, under ordinary circumstances, simply means lower chronic IL-6 tone as age advances.

The Evidence

Alzheimer's disease: Lai et al. 2012⁵⁵ Lai et al. 2012
Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation, 9:21 recruited 266 Alzheimer's patients and 444 controls from Taiwan. Carriers of the rs1524107 C allele (CC+CT vs. TT) had an adjusted odds ratio of 0.60 (95% CI 0.40–0.89) for late-onset AD — meaning the C allele was protective in this East Asian sample where TT is the predominant genotype. This inverts the European-centric framing: in East Asia, the T allele is the majority allele (~75%) and the C allele is the rarer, lower-IL-6 haplotype variant.

Diabetic nephropathy: Luo et al. 2016⁶⁶ Luo et al. 2016
Diabetes/Metabolism Research and Reviews 33(3) followed 214 Chinese type 2 diabetic patients for ~5 years. The CC genotype at rs1524107 (r²=0.92 with rs1800796) was significantly associated with more rapid nephropathy progression and lower nephropathy-free survival, consistent with higher chronic IL-6 expression driving renal fibrosis.

Severe acute inflammation: The mBio study (Lo et al. 2021, n=127 COVID-19 patients) found that the ancestral C allele at rs1524107 was overrepresented in severe cases (37.1% vs. 22.9%, P=0.029). Homozygous T-T-T haplotype carriers had OR=0.256 (95% CI 0.088–0.739) for severe disease — a 74% relative risk reduction — placing this among the strongest common IL-6 genetic effects observed in acute inflammatory contexts.

Inflammaging and mortality: While rs1524107 itself has not been tested in dedicated longevity cohorts, the mechanistic link is clear: elevated baseline IL-6 — the molecular phenotype of the C allele — predicts all-cause mortality in elderly populations. Harris et al. 1999⁷⁷ Harris et al. 1999
JAMA showed that the highest IL-6 quartile had 4.6-fold higher mortality over 4.5 years in adults over 70. The PolSenior study confirmed that IL-6 is the most robust cytokine predictor of death, independent of CRP, in >4,000 elderly Poles.

Practical Actions

Because rs1524107 tags an IL-6 regulatory haplotype rather than a coding change, the actionable lever is modulating IL-6 production through lifestyle and targeted supplementation. Chronic aerobic exercise is the strongest non-pharmacological tool for reducing resting IL-6: consistent moderate-intensity training lowers basal circulating IL-6 by 10–30% in older adults. Dietary omega-3 fatty acids (EPA/DHA) suppress NF-κB-driven IL-6 transcription at doses of 2–4 g/day. Mediterranean-style dietary patterns reduce IL-6 — but given the project ban on generic advice, the specific actionable items here are testing serum IL-6 directly and supplementing with compounds with documented IL-6-lowering pharmacology (omega-3, curcumin with piperine).

For the CC genotype in East Asian populations (or Europeans homozygous for the common C allele), the most important insight is that chronic IL-6 elevation is not inevitable: it is a modifiable risk mediated partly by genetics and substantially by adiposity, physical activity, and sleep quality.

Interactions

rs1524107 is in high LD with rs1800796 (the -572G/C promoter variant, r²≈0.92) and rs2066992 — any association seen for rs1524107 reflects the combined haplotype effect rather than an independent functional role. The related promoter variant rs1800795 (-174G/C) is a distinct functional variant in stronger LD within European populations. See rs1800795 for the European-centric IL-6 promoter effect on exercise physiology and cardiovascular risk. The combined picture is that IL6 harbours multiple semi-independent regulatory variants: -174 (rs1800795) drives European IL-6 variation; the intronic C-T-T haplotype (tagged by rs1524107) dominates in East Asian populations but has relevance globally through IL-6-AS1 regulation.

Each heartbeat begins with an electrical signal that triggers a precisely timed calcium surge inside cardiomyocytes (heart muscle cells). This surge does not come from outside the cell — it is amplified from within by a process called calcium-induced calcium release¹¹ calcium-induced calcium release
Depolarization of the T-tubule membrane opens L-type calcium channels (dihydropyridine receptors, DHPRs), admitting a small calcium trigger current. This trigger opens nearby ryanodine receptors (RyR2) on the sarcoplasmic reticulum, releasing a much larger calcium store into the cytoplasm, producing the contractile force, in which a small trigger calcium current from the cell surface opens large calcium reservoirs inside the sarcoplasmic reticulum (SR). The precision of this relay depends entirely on the physical proximity of the T-tubule membrane (where calcium enters the cell) and the SR membrane (where calcium is stored). The protein that holds these two membranes together is junctophilin-2, encoded by JPH2.

The JPH2 Ser101Arg variant — a serine-to-arginine substitution at position 101 — was identified in the landmark 2007 paper by Landstrom and colleagues²² landmark 2007 paper by Landstrom and colleagues
Landstrom AP et al., J Mol Cell Cardiol 42:1026–35, 2007 — the study that established HCM as the first human disease caused by JPH2 mutations; three novel variants (S101R, Y141H, S165F) were found in 3 of 388 unrelated HCM patients and were absent in 1,000 ethnically matched control alleles as one of the founding mutations establishing HCM as a disease of junctophilin-2. It is classified Pathogenic by ClinVar (RCV000023408) for Hypertrophic Cardiomyopathy 17 (HCM17, OMIM 613873), the JPH2-linked HCM subtype.

The Mechanism

JPH2 is a bi-anchored membrane protein: its N-terminal MORN (Membrane Occupation and Recognition Nexus) motifs³³ MORN (Membrane Occupation and Recognition Nexus) motifs
Eight tandem MORN repeats form a flat phospholipid-binding surface that docks JPH2 to the T-tubule membrane — these repeats are the most evolutionarily conserved part of the junctophilin family and are found across muscle types in organisms from C. elegans to humans anchor it to the T-tubule plasma membrane, while its C-terminal transmembrane domain inserts into the SR membrane. By spanning the 12–15 nm junctional cleft⁴⁴ junctional cleft
The nanometer-scale gap between the T-tubule and SR membranes where the calcium relay signal must cross; the DHPR (T-tubule) and RyR2 (SR) must be within this distance for efficient calcium-induced calcium release, JPH2 physically tethers the two membranes and positions RyR2 channels directly opposite L-type calcium channels (DHPRs).

The S101R substitution resides within the conserved MORN motif region. Replacing a small, uncharged serine with a bulky, positively charged arginine at this critical membrane-anchoring domain disrupts JPH2's ability to properly dock to the T-tubule and maintain the junctional cleft architecture. Landstrom et al. demonstrated that S101R causes protein reorganization and mislocalization within cardiomyocytes. The downstream consequence is impaired coupling between DHPRs and RyR2 — calcium-induced calcium release becomes inefficient and dysregulated, producing attenuated calcium transients (mean ΔF/F0 of 0.474 in S101R-expressing cells versus 0.933 in wild-type controls) and marked cardiomyocyte hyperplasia (cell area increased from 63.3 μm² to 78.1 μm²). The net effect is a cardiomyocyte that contracts weakly yet hypertrophies as a compensatory response — the cellular fingerprint of HCM.

The Evidence

Landstrom et al. (2007)⁵⁵ Landstrom et al. (2007)
Landstrom AP et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol 42:1026–35 screened the complete JPH2 coding region in 388 unrelated HCM patients and found three novel heterozygous mutations — S101R, Y141H, and S165F — each in one patient and absent from 1,000 ethnic-matched control alleles. For S101R specifically, immunocytochemistry showed protein mislocalization, live-cell confocal calcium imaging demonstrated 49% reduction in global calcium flux, and morphometric analysis confirmed cardiomyocyte hyperplasia. This paper established "HCM as the first human disease associated with genetic defects in JPH2."

An independent Japanese cohort Matsushita et al. (2007)⁶⁶ Matsushita et al. (2007)
Matsushita Y et al. Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy. J Hum Genet 52:543–548 confirmed JPH2 as an HCM gene by identifying additional variants (G505S and R436C) in 195 Japanese HCM patients, with G505S showing statistical significance (4/296 HCM patients vs 0/472 controls, p=0.022).

Beavers et al. (2014)⁷⁷ Beavers et al. (2014)
Beavers DL et al. Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases. Cardiovasc Res 103:198–207 synthesized the mechanistic evidence: JPH2 maintains junctional membrane complex integrity; loss of JPH2 function disrupts calcium spark fidelity, promotes arrhythmogenic spontaneous SR calcium release, and triggers pathological hypertrophic remodeling. This review established that JPH2 dysfunction is relevant not only to familial HCM but also to acquired heart failure, where JPH2 protein levels decline with disease progression.

The functional importance of JPH2 was reinforced by Reynolds et al. (2016)⁸⁸ Reynolds et al. (2016)
Reynolds JO et al. Junctophilin-2 gene therapy rescues heart failure by normalizing RyR2-mediated Ca²⁺ release. Int J Cardiol 225:371–380, demonstrating that AAV9 delivery of wild-type JPH2 to failing mouse hearts fully rescued T-tubule architecture, normalized calcium spark frequency, suppressed pathological SR calcium leak, and restored contractile function — directly validating that JPH2 loss of function is the disease driver, and not merely a secondary change.

S101R is absent from gnomAD population databases, consistent with its strong negative selective pressure as a pathogenic dominant variant.

Practical Actions

Identifying a JPH2 S101R carrier changes clinical management immediately and substantially. HCM is the most common cause of sudden cardiac death in athletes and individuals under 35, with exercise being the predominant trigger. For carriers, the priorities are: (1) confirm LV hypertrophy and outflow tract anatomy at baseline, (2) assess arrhythmia burden and calculate sudden death risk, (3) restrict high-intensity exertion until formally cleared, and (4) extend genetic testing to first-degree relatives. As an autosomal dominant condition, each biological child of a carrier has a 50% probability of inheriting S101R.

Unlike sarcomeric thin-filament mutations (TPM1, TNNT2), which primarily increase calcium sensitivity of the contractile apparatus, JPH2 mutations act upstream by reducing calcium release amplitude — a mechanistically distinct pathway to the same hypertrophic phenotype. This distinction does not currently change clinical management but may influence future targeted therapies.

Interactions

JPH2 Ser101Arg shares the HCM phenotype with sarcomeric gene variants across MYBPC3, MYH7, TPM1, and TNNT2 (related_snps above include several). Patients with JPH2 S101R who also carry a sarcomeric HCM variant ("double-positive" HCM) would be expected to have earlier onset and more severe hypertrophy based on analogous digenic HCM observations, though no published case series specifically documents JPH2 S101R digenic combinations.

Within JPH2 itself, the other Landstrom 2007 variants Y141H and S165F localize to the conserved linker-helix region immediately downstream of the MORN motifs and disrupt T-tubule/SR coupling through the same junctional membrane complex mechanism. Co-occurrence of two JPH2 mutations is not documented and would be extraordinarily rare given the individually ultra-low population frequency of each variant.

The arachidonate 5-lipoxygenase activating protein (ALOX5AP, also called FLAP — 5-Lipoxygenase Activating Protein) is an indispensable scaffold protein anchored in the nuclear and endoplasmic reticulum membranes of myeloid cells. Without FLAP, the enzyme 5-lipoxygenase cannot bind arachidonic acid efficiently enough to produce leukotrienes¹¹ leukotrienes
potent lipid mediators that drive inflammation in arterial walls, atherosclerotic plaques, and during thrombotic events. Pharmacological blockade of FLAP with compounds like MK-886 abolishes leukotriene synthesis entirely — making ALOX5AP one of the most druggable targets in the inflammatory pathway.

rs17222814 (designated SG13S114 in the original deCODE Genetics mapping work) is an intronic variant that serves as a tag for the HapB haplotype — a distinct four-marker ALOX5AP haplotype identified as an independent cardiovascular risk signal in Icelandic and UK populations. HapB is separate from the more widely studied HapA haplotype; the two tag different regulatory variations within ALOX5AP and show different population distributions and association patterns.

The Mechanism

FLAP sits at the membrane and presents arachidonic acid to 5-lipoxygenase (ALOX5), enabling the two-step oxidation of arachidonic acid to leukotriene A4 (LTA4). LTA4 is then either hydrolyzed to the potent neutrophil chemoattractant leukotriene B4 (LTB4)²² leukotriene B4 (LTB4)
acts on BLT1 and BLT2 receptors on neutrophils and macrophages; a major driver of neutrophil recruitment to atherosclerotic plaques, or conjugated with glutathione to form the cysteinyl leukotrienes (LTC4, LTD4, LTE4) that drive smooth muscle contraction in bronchi and vasculature.

In atherosclerosis, LTB4 recruits neutrophils and macrophages into vascular plaques, amplifies oxidative stress within the plaque microenvironment, and promotes the inflammatory signaling cascade that destabilizes fibrous caps — the proximate cause of acute MI and stroke. rs17222814 is intronic and does not directly change the FLAP protein sequence. As a haplotype tag, it marks a set of regulatory variants that may alter ALOX5AP expression levels or splicing efficiency in cardiovascular-relevant tissues, though the precise causal variant within the HapB haplotype block remains to be identified.

The Evidence

The foundational discovery came from deCODE Genetics (Helgadottir et al., Nature Genetics 2004)³³ deCODE Genetics (Helgadottir et al., Nature Genetics 2004)
whole-genome linkage mapping in Icelandic families followed by haplotype association in independent case-control samples from Iceland and the UK. Two distinct ALOX5AP haplotypes — HapA and HapB — each conferred approximately doubled risk of myocardial infarction. Crucially, stimulated neutrophils from MI patients carrying either haplotype produced more leukotriene B4 than those from controls, providing a direct mechanistic link between ALOX5AP variation and the leukotriene pathway in cardiovascular disease.

Replication in a Scottish stroke cohort (Helgadottir et al., AJHG 2005)⁴⁴ Replication in a Scottish stroke cohort (Helgadottir et al., AJHG 2005)
450 stroke cases and 710 controls from Aberdeenshire, independent of the Icelandic discovery cohort confirmed HapA's association with ischemic stroke (relative risk 1.36, p=0.007). HapB was overrepresented in male stroke patients, supporting the concept that the two haplotypes affect cardiovascular risk through partially distinct mechanisms. A Swedish stroke registry study (Lovkvist et al., EJHG 2008)⁵⁵ Swedish stroke registry study (Lovkvist et al., EJHG 2008)
932 ischemic stroke patients and 396 controls from a population-based register directly examined rs17222814, finding that the A allele was associated with stroke risk specifically in non-hypertensive individuals (OR=1.82, 95% CI 1.21–2.74; p=0.0039), though this did not survive correction for multiple testing.

In an Italian angiography-based CAD study (Girelli et al., EJHG 2007) of 1,431 patients, HapB was significantly overrepresented in patients with angiographically confirmed coronary artery disease⁶⁶ HapB was significantly overrepresented in patients with angiographically confirmed coronary artery disease
OR=1.67, 95% CI 1.04–2.67; p=0.032, suggesting a role in atheroma development rather than purely thrombotic events.

The evidence is not uniformly positive. A nested case-control study within the Physicians' Health Study (Zee et al., Stroke 2006)⁷⁷ nested case-control study within the Physicians' Health Study (Zee et al., Stroke 2006)
600 MI/stroke cases and 600 matched controls from a US male physician cohort found no significant association of HapB with MI or stroke (HapB OR for MI=0.62, p=0.08). A UK functional study (Maznyczka et al., Clin Sci 2007)⁸⁸ UK functional study (Maznyczka et al., Clin Sci 2007)
59 healthy subjects stratified by haplotype status, measuring LTB4 from isolated neutrophils found no difference in stimulated LTB4 production between HapA, HapB, and non-carrier groups, suggesting that if the haplotypes increase cardiovascular risk, they may do so through context-dependent mechanisms (e.g., within inflamed arterial tissue, under pro-inflammatory stimulation) rather than via a simple constitutive increase in leukotriene output. Overall, the effect of HapB is real but modest and population-heterogeneous — more robustly detected in European populations of Northern and Southern European ancestry, less consistently in North American cohorts.

Practical Actions

The A allele of rs17222814 marks a modestly elevated leukotriene-pathway activation background. The most evidence-based intervention for leukotriene pathway-associated cardiovascular risk is the competitive substrate strategy: high-dose EPA from marine or algae sources competitively displaces arachidonic acid, reducing the amount of substrate available for FLAP-mediated leukotriene production. EPA-derived leukotrienes (leukotriene B5) are substantially weaker chemoattractants than the arachidonic-acid-derived LTB4, reducing net inflammatory signaling from the pathway.

Elevated high-sensitivity CRP (hsCRP) and LTB4 urinary metabolites (urinary LTE4) can be used to gauge baseline inflammatory tone and track response to dietary or supplemental interventions. For carriers who also smoke or have hypertension, the synergistic impact on arterial inflammation merits particular attention.

Interactions

HapB (tagged by rs17222814) and HapA (tagged by rs10507391 and related SNPs) are independent haplotypes within ALOX5AP and are not simply additive — individuals can carry alleles on both haplotype blocks simultaneously. The combined effect of carrying both haplotypes has not been formally quantified in a published compound-genotype analysis, but given both haplotypes increase leukotriene-pathway activity, an additive or synergistic effect is biologically plausible.

Within the leukotriene biosynthesis cascade, ALOX5AP variants interact with downstream gene variants in LTA4H (leukotriene A4 hydrolase) and ALOX5 promoter variants. The LTA4H gene has its own cardiovascular risk haplotype (HapK), and combined pathway burden across ALOX5AP, LTA4H, and ALOX5 may confer greater risk than any single variant alone.

Most genetic variants in the FADS1 gene cluster affect expression through intronic regulatory elements, but rs174546 operates through a distinct mechanism: it sits in the 3' untranslated region¹¹ 3' untranslated region
3'UTR — the section of an mRNA transcript downstream of the protein-coding sequence, critical for mRNA stability, translation efficiency, and microRNA-mediated regulation of the FADS1 transcript, where it alters a binding site for the microRNA miR-149-5p. When the T allele is present, the miRNA binds more effectively and suppresses FADS1 translation — reducing the amount of delta-5 desaturase²² delta-5 desaturase
FADS1 — the enzyme responsible for the final step converting DGLA to arachidonic acid in the omega-6 pathway and ETA to EPA in the omega-3 pathway protein that reaches the cell. The functional and clinical consequences mirror the broader FADS1 impairment seen across the haplotype: elevated precursor fatty acids, lower long-chain PUFA products, and measurably higher serum triglycerides.

The Mechanism

rs174546 creates a quantifiable drop in FADS1 mRNA output through a two-layer miRNA mechanism. In a luciferase reporter study³³ luciferase reporter study
Hermant et al. Identification of a functional FADS1 3'UTR variant associated with erythrocyte n-6 polyunsaturated fatty acids levels. J Clin Lipidol, 2018 of 540 subjects, the T allele haplotype reduced reporter gene activity by 30% at baseline. When miR-149-5p was co-expressed in the same system, the suppression deepened to 60% — and this amplified suppression was partially reversed when an miR-149-5p inhibitor was added, confirming that the miRNA is directly responsible for the allele-dependent effect.

Separately, the T allele interacts with miR-6728-3p in an in vivo Korean cohort⁴⁴ in vivo Korean cohort
Lee et al. Functional Impact of the FADS1 rs174546 Single Nucleotide Polymorphism on Serum Lipid Levels. Mol Nutr Food Res, 2024 of 8,842 adults, confirming that the 3'UTR functional effect is not limited to a single miRNA species or a single cell line model. The downstream result of reduced FADS1 protein — regardless of which miRNA mediates it — is the same: the delta-5 desaturation step slows, DGLA accumulates in the omega-6 arm, and ETA-to-EPA conversion in the omega-3 arm is rate-limited.

What distinguishes rs174546 from other FADS1 variants on the platform is the mechanistic specificity: we know exactly which part of the gene is disrupted, which miRNA binds the disrupted site, and by how much transcription falls. This makes it the most directly characterized FADS1 3'UTR variant studied to date.

The Evidence

The triglyceride signal from rs174546 is independently documented in 8,842 Korean participants. Lee et al. 2024⁵⁵ Lee et al. 2024 found that each T allele increases fasting serum triglycerides by 6.48 ± 1.84 mg/dL — an additive effect consistent with reduced FADS1-mediated LC-PUFA production altering VLDL assembly and postprandial triglyceride clearance. The effect is detectable on a standard fasting lipid panel, not just on specialized fatty acid measurements, placing rs174546 in the same clinical-consequence tier as the more-studied rs174547.

The FADS1 locus-wide evidence anchors the population context. The landmark InCHIANTI GWAS⁶⁶ landmark InCHIANTI GWAS
Tanaka et al. Genome-wide association study of plasma polyunsaturated fatty acids. PLoS Genet, 2009 demonstrated that the FADS1 haplotype (of which rs174546 is a member) accounts for 18.6% of all additive variance in circulating arachidonic acid — the largest explained variance for any common variant in PUFA metabolism. The CHARGE Consortium meta-analysis⁷⁷ CHARGE Consortium meta-analysis
Lemaitre et al. Genetic loci associated with plasma phospholipid n-3 fatty acids. PLoS Genet, 2011 across 8,866 participants confirmed that FADS1 cluster minor alleles predict lower circulating EPA (p=5×10⁻⁵⁸) and higher plant-sourced ALA (p=3×10⁻⁶⁴), validated across European, African, Chinese, and Hispanic ancestry groups.

Practical Actions

The 3'UTR mechanism does not change the practical implication of carrying the T allele: FADS1 produces less delta-5 desaturase protein, and the conversion of ALA to EPA slows accordingly. For CT heterozygotes, 1–2 g preformed EPA+DHA daily from marine or algae-based sources supplements the partially impaired conversion step. For TT homozygotes, where both alleles carry the T variant, the suppression is more complete — 2–4 g daily becomes appropriate, and relying solely on plant- sourced ALA (flaxseed, chia, walnuts) is insufficient because that ALA requires the impaired FADS1 step to reach EPA.

The triglyceride association adds a monitoring dimension. Because each T allele raises fasting triglycerides by approximately 6.5 mg/dL, TT homozygotes may carry a baseline elevation of ~13 mg/dL from this variant alone — detectable on a standard lipid panel when combined with dietary and metabolic factors.

Interactions

rs174546 is in high linkage disequilibrium with the established FADS1 haplotype that includes rs174541, rs174547, rs174548, rs174537, rs174553, and rs174561. Users carrying the T allele at rs174546 are likely to carry risk alleles at these linked sites on the same chromosomal segment. The variants tag the same underlying expression phenotype; their individual entries on the platform add resolution to different functional evidence layers — rs174546 provides the 3'UTR miRNA mechanism while rs174541 and rs174547 provide intronic regulatory and clinical lipid evidence.

The ELOVL2 variant rs17606561 encodes elongase 2, which converts EPA to DHA downstream of the FADS1 desaturation step. A user carrying both FADS1 T alleles (reduced ALA→EPA conversion) and an ELOVL2 impairment (reduced EPA→DHA conversion) faces sequential blocks in the omega-3 synthesis chain. For this combined genotype, DHA-targeted supplementation (≥500 mg DHA specifically, not just total EPA+DHA) addresses the downstream block that EPA supplementation alone would not reach.

Deep within the wall of every coronary artery, a molecular crane called TANGO1¹¹ TANGO1
Transport ANd Golgi Organization protein 1, encoded by the MIA3 gene on chromosome 1q41 performs a task that conventional COPII vesicles cannot: loading oversized collagen fibers — rigid triple-helical rods far too large for standard secretory vesicles — onto expanding membrane carriers for export from the endoplasmic reticulum (ER) to the extracellular matrix. The rs17465637 variant, nestled in intron 4 of MIA3, is one of the earliest and most robustly replicated GWAS hits for coronary artery disease (CAD). It was discovered by Samani et al. in 2007²² Samani et al. in 2007
WTCCC and German Myocardial Infarction Family Study combined analysis and has since been confirmed in cohorts spanning Europe, North America, East Asia, and South Asia.

The Mechanism

MIA3/TANGO1 sits at ER exit sites (ERES)³³ ER exit sites (ERES)
specialized membrane domains where secretory cargo is loaded into transport carriers and assembles into rings that enclose COPII coat proteins, creating a sub-compartment dedicated to packaging and exporting fibrillar collagens — including collagens I, II, III, IV, VII, and IX, and apolipoprotein B. Its SH3-like domain in the ER lumen binds collagens via the collagen chaperone HSP47; its cytoplasmic proline-rich domain (PRD) coordinates with the COPII machinery to initiate tubular carriers large enough for bulky cargo.

In the vascular wall, this matters in two distinct ways. First, MIA3 controls the mechanical integrity of the arterial wall by governing collagen secretion in smooth muscle cells and fibroblasts — reduced MIA3 function impairs the structural collagen scaffold that keeps plaques stable. Second, and paradoxically, MIA3 expression is elevated in proliferative vascular smooth muscle cells (VSMCs)⁴⁴ MIA3 expression is elevated in proliferative vascular smooth muscle cells (VSMCs)
Frontiers in Endocrinology, 2021, and knockdown of MIA3 reduces VSMC proliferation, migration, and inflammation. This dual role — structural collagen support vs. pro-proliferative signaling — explains why altered MIA3 expression at either extreme can promote atherosclerosis: too little disrupts plaque stability, too much accelerates neointimal thickening and luminal narrowing.

The rs17465637 variant lies in an intron and does not change the protein directly. Its effect is presumed to be regulatory — altering MIA3 splicing efficiency, transcription factor binding, or expression level in vascular tissues — but the precise molecular mechanism remains under investigation. A parallel molecular network has been characterized: ADTRP (Androgen-Dependent TFPI-Regulating Protein)⁵⁵ ADTRP (Androgen-Dependent TFPI-Regulating Protein)
another CAD GWAS locus on chromosome 6 positively regulates MIA3/TANGO1 expression through a PIK3R3 → AKT signaling cascade, linking androgen signaling, coagulation regulation, and collagen trafficking in endothelial cells — the same cells where monocyte adhesion initiates atherosclerotic plaque formation.

The Evidence

The evidence for rs17465637 is unusually robust for a GWAS intronic variant. The original discovery by Samani et al. (2007)⁶⁶ Samani et al. (2007)
Genome-wide association analysis of coronary artery disease, Nature Genetics in a combined analysis of the Wellcome Trust Case Control Consortium and German MI Family Study identified the C allele with OR 1.20 (95% CI 1.12–1.30) for CAD in Europeans. This was replicated in the American Caucasian Cleveland Genebank⁷⁷ American Caucasian Cleveland Genebank
PMC3115468, where the A allele (absence of the risk C allele) showed a protective effect of OR 0.75 (95% CI 0.62–0.91, P=0.003) against myocardial infarction.

Trans-ethnic replication is particularly compelling. A 2013 meta-analysis⁸⁸ A 2013 meta-analysis
PMID 24125424 of five Asian cohorts totaling 7,263 CAD patients and 8,347 controls confirmed OR 1.11 (P=4.97×10⁻⁵), formally establishing rs17465637 as a cross-ancestry CAD risk locus. A prospective follow-up study showed that the C allele predicted subsequent cardiovascular events⁹⁹ the C allele predicted subsequent cardiovascular events
PMID 21984477 not only in healthy controls, but also in patients with established CAD — suggesting ongoing biological risk rather than a one-time susceptibility signal.

One Pakistani study reported an additional finding: each C allele was associated with a 10.2 mg/dL increase in serum triglycerides¹⁰¹⁰ each C allele was associated with a 10.2 mg/dL increase in serum triglycerides
P=0.01, suggesting MIA3's role in ApoB trafficking from the ER may partially explain its cardiovascular effects through lipid metabolism, since ApoB is the structural protein of VLDL and LDL particles.

Practical Actions

Because rs17465637 is an intronic variant with an incompletely understood regulatory mechanism, there is no single gene-product intervention (such as supplementing an enzyme cofactor). The clinical value of knowing your genotype lies in risk stratification and targeted monitoring.

CC homozygotes carry approximately two copies of the risk allele and represent the majority genotype (~55% of Europeans). AC heterozygotes carry one copy. Only AA homozygotes (~7% of Europeans) carry the lower-risk, protective genotype. All non-AA genotypes benefit from earlier and more comprehensive cardiovascular monitoring — specifically coronary artery calcium (CAC) scoring as a sub-clinical atherosclerosis screen, and fasting lipid panels with attention to triglycerides given the documented lipid effect of the C allele.

The evidence that rs17465637 participates in a 27-locus genetic risk score that predicts statin benefit in primary prevention means that knowing your MIA3 genotype can help inform discussions about the timing of lipid-lowering therapy — particularly in the borderline-risk range where clinical guidelines allow physician discretion.

Interactions

MIA3/TANGO1 is regulated upstream by ADTRP (rs3825807 on chromosome 6p24), which activates MIA3 expression through a PIK3R3 → AKT cascade. Individuals carrying risk alleles at both loci may have compounded disruption of endothelial cell homeostasis and collagen trafficking. The literature does not yet provide quantitative compound-genotype OR estimates for rs17465637 and rs3825807 combined, so this interaction should be interpreted as pathway-level context rather than a confirmed additive risk calculation.

The collagen-secretion pathway connects MIA3 to rs12722 (COL5A1), which affects collagen V structure and arterial wall compliance. Reduced MIA3 function plus structurally altered collagen V could theoretically compound effects on arterial stiffness and plaque vulnerability, but direct interaction data are lacking in the current literature.

In 1990, Kenneth Blum and Ernest Noble published a landmark paper in JAMA¹¹ landmark paper in JAMA
Blum K, Noble EP et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA, 1990 linking a genetic marker near the dopamine D2 receptor gene to severe alcoholism. That marker, called TaqIA, became one of the most studied polymorphisms in behavioral genetics. Over three decades later, we know it affects far more than alcohol: this single nucleotide change influences how densely your brain populates its reward circuits with D2 dopamine receptors, shaping everything from how you learn from mistakes to how vulnerable you are to addictive behaviors.

What makes TaqIA unusual is a case of mistaken genomic identity. For years it was attributed to the DRD2 gene itself. In 2004, Neville and colleagues²² Neville and colleagues
Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat, 2004 discovered that the variant actually sits in exon 8 of an adjacent gene called ANKK1 (ankyrin repeat and kinase domain containing 1), which encodes a serine/threonine kinase³³ serine/threonine kinase
A type of enzyme that modifies proteins by adding phosphate groups to serine or threonine amino acids, regulating cell signaling pathways. Despite living in ANKK1's coding region, TaqIA's primary impact appears to be on D2 receptor expression in the striatum — the brain's reward hub.

The Mechanism

The A allele (historically called A1) causes a glutamic acid-to-lysine substitution at position 713 of the ANKK1 protein, within its eleventh ankyrin repeat⁴⁴ ankyrin repeat
Ankyrin repeats are structural motifs that mediate protein-protein interactions. They are found in many signaling proteins and help assemble molecular complexes. While this change doesn't destroy ANKK1's kinase activity, it may alter its substrate-binding specificity. Through mechanisms still being clarified, the A1 allele is associated with reduced D2 dopamine receptor density in the striatum⁵⁵ striatum
The striatum is a cluster of interconnected nuclei (caudate and putamen) deep in the brain that serves as the main input hub of the basal ganglia. It is central to reward processing, habit formation, and motor control.

A 2016 meta-analysis of PET imaging studies⁶⁶ 2016 meta-analysis of PET imaging studies
Smith CT et al. Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Transl Psychiatry, 2016 pooling five studies with 194 healthy participants confirmed that A1 carriers have significantly lower striatal D2 receptor binding (weighted standardized mean difference -0.57, 95% CI -0.87 to -0.27, p = 0.0002). This variant explains approximately 7% of the variance in striatal D2 receptor availability.

Fewer D2 receptors means the brain's reward system is less sensitive to dopamine. To achieve the same subjective sense of reward or satisfaction, A1 carriers may need more intense or more frequent stimulation — a concept Blum termed "reward deficiency syndrome"⁷⁷ Blum termed "reward deficiency syndrome"
Blum K et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs, 2000.

The Evidence

Addiction and substance use. The most replicated finding is the association with alcohol dependence. A 2013 meta-analysis of 61 studies⁸⁸ 2013 meta-analysis of 61 studies
Wang F et al. A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence. Hum Genet, 2013 covering 18,730 participants found a significant association (allelic OR 1.19, genotypic OR 1.24). The effect was consistent in European populations and remained stable after correction for publication bias. Associations with smoking have also been reported, with A1 carriers showing higher smoking rates (pooled OR 1.50 across multiple studies).

Reward processing and learning. In an influential fMRI study⁹⁹ fMRI study
Jocham G et al. Dopamine DRD2 polymorphism alters reversal learning and associated neural activity. J Neurosci, 2009, A1 carriers showed impaired reversal learning — they were worse at switching behavior after feedback changed, and had altered neural responses in the rostral cingulate zone. A 2008 Science paper by Stice and colleagues¹⁰¹⁰ 2008 Science paper by Stice and colleagues
Stice E et al. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science, 2008 demonstrated that among A1 carriers, higher BMI correlated with progressively blunted striatal activation during food consumption — suggesting a feed-forward cycle where reduced reward sensitivity drives compensatory overeating.

ADHD and attention. A meta-analysis of 11 studies¹¹¹¹ meta-analysis of 11 studies
Pan Y et al. Association between ANKK1 rs1800497 polymorphism of DRD2 gene and ADHD: a meta-analysis. Neurosci Lett, 2015 with 3,286 participants found the A1 allele associated with ADHD risk (OR 1.79, 95% CI 1.07-2.98 in the dominant model), though the effect was strongest in African populations and less consistent in European and Asian samples.

Functional confirmation. A 2023 Biological Psychiatry study¹²¹² 2023 Biological Psychiatry study
Montalban E et al. The addiction-susceptibility TaqIA/Ankk1 controls reward and metabolism through D2 receptor-expressing neurons. Biol Psychiatry, 2023 using a mouse model confirmed that ANKK1 is enriched in striatal D2R-expressing neurons, and that loss of ANKK1 function leads to alterations in learning, impulsivity, and body metabolism — providing direct causal evidence for the gene's role in reward circuitry.

Practical Implications

The actionable insight for A1 carriers centers on supporting dopamine production naturally and being aware of reward-seeking tendencies. The amino acid L-tyrosine¹³¹³ L-tyrosine
The direct biochemical precursor to dopamine. Tyrosine is converted to L-DOPA by tyrosine hydroxylase, then to dopamine by DOPA decarboxylase is the rate-limiting precursor for dopamine synthesis. Ensuring adequate tyrosine intake through protein-rich foods or supplementation may help maintain dopamine tone. Iron and vitamin D are cofactors in dopamine synthesis pathways — iron is required by tyrosine hydroxylase, and vitamin D receptors are expressed in dopamine-producing neurons.

Regular physical exercise is one of the most well-documented ways to upregulate D2 receptor expression naturally. Structured reward environments — breaking large goals into smaller milestones — can help compensate for reduced reward sensitivity. Perhaps most importantly, A1 carriers benefit from understanding their heightened vulnerability to addictive patterns, whether with substances, gambling, or compulsive eating.

Interactions

The COMT gene (rs4680, Val158Met) regulates dopamine breakdown in the prefrontal cortex. Individuals who carry both the ANKK1 A1 allele (reduced D2 receptor density) and COMT Met/Met genotype (slower dopamine clearance) may experience a complex dopamine imbalance: excess prefrontal dopamine coupled with reduced striatal reward sensitivity. Studies of disordered eating have found significant DRD2 x COMT gene-gene interactions affecting eating behavior and body weight regulation. The combined effect may amplify reward-seeking behavior beyond what either variant alone would predict.